Article (Scientific journals)
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity
Cruyssen, B. V.; Van Looy, S.; Wyns, B. et al.
2006In Arthritis Research and Therapy, 8 (4), p. 112
Peer Reviewed verified by ORBi
 

Files


Full Text
Malaise_2006_ArthritisResTher_R112.pdf
Publisher postprint (456.85 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Interleukin-6; Leptin; Bone Resorption; Apoptosis; Cell Differentiation; Cell Proliferation
Abstract :
[en] Although there is strong evidence supporting the short-term efficacy and safety of anti-tumour necrosis factor-alpha agents, few studies have examined the long-term effects. We evaluated 511 patients with long-standing refractory rheumatoid arthritis treated with intravenous infusions of infliximab 3 mg/kg at weeks 0, 2, 6, and 14 and every 8 weeks thereafter for 4 years. Among the initial 511 patients included in the study, 479 could be evaluated; of these, 295 (61.6%) were still receiving infliximab treatment at year 4 of follow-up. The most common reasons for treatment discontinuation were lack of efficacy (65 patients, 13.6%), safety (81 patients, 16.9%), and elective change (38 patients, 7.9%). Analysis of disease activity scores (DAS28 [ disease activity score based on the 28-joint count]) over time showed that, after the initial rapid improvement during the first 6 to 22 weeks of therapy, a further decrease in disease activity of 0.2 units in the DAS28 score per year was observed. DAS28 scores, measured at week 14 or 22, were found to predict subsequent discontinuation due to lack of efficacy. In conclusion, long-term maintenance therapy with infliximab 3 mg/kg is effective in producing further reductions in disease activity. Disease activity measured by the DAS28 at week 14 or 22 of infliximab therapy was the best predictor of long-term attrition.
Disciplines :
Rheumatology
Author, co-author :
Cruyssen, B. V.
Van Looy, S.
Wyns, B.
Westhovens, R.
Durez, P.
Van den Bosch, F.
Mielants, H.
De Clerck, L.
Peretz, A.
Malaise, Michel ;  Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie
Verbruggen, L.
Vastesaeger, N.
Geldhof, A.
Boullart, L.
De Keyser, F.
More authors (5 more) Less
Language :
English
Title :
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity
Publication date :
2006
Journal title :
Arthritis Research and Therapy
ISSN :
1478-6354
eISSN :
1478-6362
Publisher :
BioMed Central, London, United Kingdom
Volume :
8
Issue :
4
Pages :
R112
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 19 September 2010

Statistics


Number of views
47 (2 by ULiège)
Number of downloads
37 (2 by ULiège)

Scopus citations®
 
44
Scopus citations®
without self-citations
36
OpenCitations
 
32

Bibliography


Similar publications



Contact ORBi